论文部分内容阅读
目的:探讨恶性淋巴瘤患者血清CEA、CA125、LDH、β2-MG水平及其与临床分期和预后的关系。方法:选择2014年1月-2016年1月我院血液内科收治的86例ML患者纳入观察组,选择同期健康体检者50例纳入对照组,比较两组研究对象血清CEA、CA125、LDH、β2-MG水平;同时比较不同临床分期及治疗效果的ML其血清CEA、CA125、LDH、β2-MG水平的差异。结果:观察组血清CEA、CA125、LDH、β2-MG水平均明显高于对照组,差异均有统计学意义(P<0.05);临床分期为Ⅲ-Ⅳ期的ML患者其血清CEA、CA125、LDH、β2-MG水平明显高于临床分期为Ⅰ-Ⅱ期者,差异有统计学意义(P<0.05);本研究86例患者中有68例患者为治疗有效纳入有效组,18例患者治疗无效纳入无效组;有效组患者治疗后血清CEA、CA125、LDH、β2-MG水平较治疗前明显下降,且低于无效组,差异均有统计学意义(P<0.05)。结论:血清CEA、CA125、LDH、β2-MG水平在ML患者可明显增高,且监测其水平变化对ML患者临床分期及近期疗效的判断具有重要意义。
Objective: To investigate the serum levels of CEA, CA125, LDH and β2-MG in patients with malignant lymphoma and their relationship with clinical stage and prognosis. Methods: From January 2014 to January 2016, 86 ML patients admitted to Department of Hematology of our hospital were enrolled in the observation group. 50 healthy subjects were enrolled in the control group. The serum levels of CEA, CA125, LDH, β2 -MG levels; at the same time, different serum levels of CEA, CA125, LDH and β2-MG were compared among different clinical stages and therapeutic effects. Results: The levels of serum CEA, CA125, LDH and β2-MG in the observation group were significantly higher than those in the control group (P <0.05). Serum CEA, CA125, LDH, β2-MG levels were significantly higher than the clinical stage Ⅰ-Ⅱ, the difference was statistically significant (P <0.05); 68 patients in this study, 68 patients were included in the effective treatment group, 18 patients treated In the effective group, the serum levels of CEA, CA125, LDH and β2-MG were significantly lower than those before treatment and lower than those of the ineffective group (P <0.05). Conclusion: Serum levels of CEA, CA125, LDH and β2-MG may be significantly increased in patients with ML, and monitoring the level of serum CEA, CA125, LDH and β2-MG is of great significance for the clinical staging and short-term curative effect of ML patients.